The B Cell and Rheumatoid Arthritis Part I: Rituximab (Rituxan), a B Cell Depleting Agent, Rheumatoid Factor (RF) and Joint Immune Aggregates Part I Page 36
Windows Media Player
QuickTime Media Player
Real Media Player
A B-cell making rheumatoid factors is shown, and a B-cell depleting agent is described.
Also, in current research trials, an anti-B Cell agent, Rituximab, has been shown to have similar benefit. The production of autoantibody, rheumatoid factor, is the most constant immunologic perturbation found in rheumatoid arthritis patients, and the rheumatoid joint produces and contains huge quantities of immunoglobulin. A B-cell depleting agent would attack the source of immune aggregates and rheumatoid factor. These trials have been inspired by research emphasizing a B-cell centric and joint centric mechanism for the pathogenesis of rheumatoid arthritis.
Page 36
Slide 4: "The B-cell Centric, Joint Centric Mechanism for Rheumatoid Arthritis " 360 x 240 pixels 15kb drawn freehand in 3dStudio Max
......Index 
Go to Previous page .....Go to Next page
